Bleeding Disorders
From the Journals
Coagulopathy outbreak underscores danger of synthetic cannabinoids
Four patients died after developing spontaneous intracranial bleeding.
News
Product approved to treat hemophilia A in Japan
The Japanese Ministry of Health, Labour and Welfare has approved Jivi® (also known as damoctocog alfa pegol or antihemophilic factor [recombinant...
From the Journals
Eltrombopag irons out kinks in hematopoiesis
The thrombopoietin-receptor agonist’s iron-chelating action stimulates hematopoietic stem cell activity, independent of the thrombopoietin...
News
CHMP recommends factor VIII therapy for hemophilia A
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for damoctocog alfa pegol, a...
Conference Coverage
Drug-coated stent bests bare metal in patients with high bleeding risk
SAN DIEGO – Positive
Feature
Von Willebrand disease product approved in Europe
Vonicog alfa (Veyvondi) is approved to treat or prevent bleeding in certain adults with von Willebrand disease.
News
EC approves product for von Willebrand disease
The European Commission (EC) has granted marketing authorization for vonicog alfa (Veyvondi), a recombinant von Willebrand factor (rVWF) product...
News
Hemophilia B drug available in larger vial
CSL Behring has announced that Idelvion (Coagulation Factor IX [Recombinant], Albumin Fusion Protein) is now available in a 3500 IU vial size....
Latest News
Caplacizumab approved in Europe to treat aTTP
The drug is under priority review by the U.S. Food and Drug Administration.
News
Caplacizumab approved to treat aTTP
The European Commission has granted marketing authorization for caplacizumab (Cablivi™), a humanized bivalent nanobody that inhibits the...
News
Factor VIII product approved for hemophilia A
The US Food and Drug Administration (FDA) has approved Jivi® (antihemophilic factor [recombinant] PEGylated-aucl) for the treatment of hemophilia...